Novartis Wins Landmark Approval With First Personalized CAR-T Cancer Therapy

Drug Industry Daily
A A
The FDA opened the doors to a dramatic new method for treating cancer — the genetic modification of a patient’s immune cells to fight the disease — by granting approval to Novartis’ Kymriah.

To View This Article:

Login

Subscribe To Drug Industry Daily